Advances in subcutaneous immunotherapy

    loading  Checking for direct PDF access through Ovid

Abstract

Purpose of review

Current limitations in subcutaneous immunotherapy (SCIT) include the length of time required to achieve tolerance as well as the potential for systemic side-effects. Advances in allergen immunotherapy include targeted therapies to B-cell and T-cell pathways that can lead to more rapid desensitization and potentially the prevention of allergic disease.

Recent findings

Novel molecularly engineered compounds and delivery vehicles allow for rapid and efficient desensitization. Combination with immune modifiers, treatment with epitope-based compounds, and hypoallergenic recombinant vaccines have the potential to improve immunogenicity while limiting systemic side-effects.

Summary

Advances in SCIT create new therapeutic opportunities for patients to improve safety, efficacy, and compliance. Concepts using epitope-based immunotherapy and carrier-fusion peptides have the potential to induce tolerance quickly via selective B-cell and T-cell pathways.

Related Topics

    loading  Loading Related Articles